Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and maintain remission. Treatment of CD typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) but often progresses to more-potent drugs, such as immunosuppressants and/or biologics. However, this scenario is changing, and more physicians are prescribing biologics for recently diagnosed CD. Among the biologics, TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) are the mainstays of treatment, but newer therapies, including Takeda’s Entyvio and Janssen’s Stelara, have a growing market share.
Real World data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants
Key Analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
Already a Client? Log in to access this report.
Ritesh Gupta is a Lead Analyst on the immune and inflammatory disorders team at Decision Resources Group, whose work focuses primarily on Psoriatic Arthritis, Ulcerative Colitis and Crohn’s Disease. He holds a degree in Cell Biology from Max Delbrück Center for Molecular Medicine, Berlin, where he worked on development of novel inhibitors for HGF/MET signaling pathways. Prior to joining DRG, Ritesh has worked as an assistant manager with BioXcel corporation and provided insights on various consulting projects. He was also associated with GVK Biosciences and worked on drug repurposing projects.